Alteogen Creating a New Future
Alteogen is a leading bio company whose portfolio includes next-generation biobetters, with improved efficacy in comparison with existing biologics, biosimilars that demonstrate “comparability” to the approved biologics, and proprietary biologics.
- NexP™ Fusion Technology – second-generation .persistent technology which uses human A1AT (ALPHA-1 antitrypsin) protein, abundant in human blood, as the protein carrier which increases half-life of biomedicine
NexMab™ ADC Technology – Proprietary Antibody-Drug Conjugate (ADC) technology with superior stability, efficacy, and economical feasibility
Hybrozyme Technology – Novel human hyaluronidase PH20 for subcutaneous injection with superior stability
- Biosimilars – Leading biosimilar technology
Alteogen is preparing better future by focusing on the three cutting edge areas of the industry –long-acting biobetters, proprietary antibody-drug conjugate (ADC), and antibody biosimilars with high complexity.
